Document is current
Any future updates will be listed below
-
Authors
Bonfá, Eloisa https://orcid.org/0000-0002-0520-4681
Gossec, Laure https://orcid.org/0000-0002-4528-310X
Isenberg, David A. https://orcid.org/0000-0001-9514-2455
Li, Zhanguo https://orcid.org/0000-0002-2590-6242
Raychaudhuri, Soumya https://orcid.org/0000-0002-1901-8265
- License Information
-
More Information
Article History
Accepted: 9 October 2020
First Online: 2 November 2020
Competing interests
: L.G. receives research grants from Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz and Sanofi, and receives consulting fees from AbbVie, Amgen, BMS, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis and UCB, all unrelated to the present paper. S.R. is an employee of Brigham and Women’s Hospital, and has recently served as a consultant for AbbVie, Biogen, Gilead, Merck and Pfizer. He is a founder of Mestag. He currently receives research funding from Biogen. E.B., D.A.I. and Z.L. declare no competing interests.
Free to read: This content has been made available to all.
